Breaking News Instant updates and real-time market news.

RARE

Ultragenyx

$58.85

1.94 (3.41%)

16:12
08/22/17
08/22
16:12
08/22/17
16:12

Ultragenyx Ace-ER study in GNEM patients misses primary, key secondary endpoints

Ultragenyx Pharmaceutical announced that a Phase 3 study evaluating aceneuramic acid extended release, Ace-ER, in patients with GNE Myopathy, GNEM, did not achieve its primary endpoint of demonstrating a statistically significant difference in the upper extremity muscle strength composite score compared to placebo. The study also did not meet its key secondary endpoints. Adverse events were generally balanced between Ace-ER and placebo and safety was consistent with previously released Ace-ER data. Ultragenyx plans to discontinue further clinical development of Ace-ER. "We are disappointed by these results, as we had hoped that Ace-ER would offer a new option for GNEM patients. We would like to thank the patients, caregivers, and investigators involved in the Ace-ER development program," said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. "This outcome does not affect our overall strategy, as the company moves forward with multiple preclinical and clinical programs and regulatory filings." The Phase 3 Ace-ER study enrolled 89 adults with GNEM able to walk greater than 200 meters in the six minute walk test. Patients were randomized 1:1 to Ace-ER at a dose of 6g/day or placebo for 48 weeks. The study did not meet the primary endpoint of demonstrating a statistically significant improvement in UEC score for Ace-ER treated patients compared to placebo patients for the change from baseline to 48 weeks. There were three pre-specified key secondary endpoints, including the lower extremity muscle strength composite score as measured by hand-held dynamometry, physical functioning using the Mobility domain of the GNE Myopathy-functional activity scale, and a measure of muscle strength in knee extensors. The study did not meet any of these key secondary endpoints. Overall, Ace-ER was well tolerated, with slightly more patients experiencing treatment emergent adverse events and related treatment emergent adverse events. There were three serious adverse events including two on Ace-ER and one on placebo, none of which were considered treatment related. There were no discontinuations due to treatment emergent adverse events, and there have been no deaths in the study. The company plans to terminate the development program based on these results and will work with investigators and patient groups to make available the valuable natural history data and development tools for the development of other therapies. The company will be working with investigators and patients on a reasonable transition plan for patients still on Ace-ER.

  • 16

    Nov

RARE Ultragenyx
$58.85

1.94 (3.41%)

05/05/17
LEER
05/05/17
NO CHANGE
Target $89
LEER
Outperform
Ultragenyx price target lowered to $89 from $93 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Ultragenyx to $89 from $93 as he delays launch assumptions for triheptanoin programs to 2020 from 2019. Nonetheless, the analyst notes that the company announced pre-specified fracture healing data in X-linked hypophosphatemia patients who were enrolled in the recent Phase 3 study, which suggest burosumab is disease-modifying and correlates biomarker improvements to physiological benefit. He continues to assign 90% probability of success to burosumab, and reiterates an Outperform rating on the shares.
07/27/17
BERN
07/27/17
INITIATION
BERN
Market Perform
Ultragenyx initiated with a Market Perform at Bernstein
Bernstein analyst Vincent Chen started coverage of Ultragenyx with a $72 price target and a Market Perform rating. The analyst views the stock as fully valued.
07/27/17
07/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kinder Morgan (KMI) initiated with a Neutral at Mizuho. 2. Alpine Immune Sciences (ALPN) initiated with a Buy at Ladenburg. 3. Synaptics (SYNA) resumed with an Outperform at Cowen. 4. BioMarin (BMRN) and Ultragenyx (RARE) were initiated with a Market Perform at Bernstein. 5. Keane Group (FRAC) and ProPetro Holding (PUMP) were initiated with an Overweight at Capital One. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/17
EVER
08/16/17
INITIATION
Target $63
EVER
In Line
Ultragenyx initiated with an In Line at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Ultragenyx with an In Line and a $63 price target.

TODAY'S FREE FLY STORIES

BTX

BioTime

$2.64

-0.02 (-0.75%)

07:02
01/22/18
01/22
07:02
01/22/18
07:02
Hot Stocks
BioTime sees submitting Renevia for CE mark during Q1 »

BioTime expects to submit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCN

Neovasc

$0.55

0.0313 (6.02%)

07:02
01/22/18
01/22
07:02
01/22/18
07:02
Hot Stocks
Neovasc CEO Alexei Marko to depart, Fred Colen to succeed »

Neovasc announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$57.75

-2.25 (-3.75%)

, VIA

Viacom

$39.20

-0.5 (-1.26%)

07:01
01/22/18
01/22
07:01
01/22/18
07:01
Downgrade
CBS, Viacom, Viacom rating change  »

CBS downgraded on higher…

CBS

CBS

$57.75

-2.25 (-3.75%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 08

    Feb

  • 15

    Feb

AER

AerCap

$54.11

0.38 (0.71%)

07:01
01/22/18
01/22
07:01
01/22/18
07:01
Hot Stocks
AerCap leased, purchased and sold 402 aircraft in 2017 »

AerCap Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

07:01
01/22/18
01/22
07:01
01/22/18
07:01
Hot Stocks
Bristol-Myers Yervoy expanded indication approved by EC »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

LRCX

Lam Research

$207.53

2.08 (1.01%)

, TSM

TSMC

$44.67

0.1 (0.22%)

07:00
01/22/18
01/22
07:00
01/22/18
07:00
Recommendations
Lam Research, TSMC, Ichor Holdings analyst commentary  »

Lam Research price target…

LRCX

Lam Research

$207.53

2.08 (1.01%)

TSM

TSMC

$44.67

0.1 (0.22%)

ICHR

Ichor Holdings

$32.39

-0.36 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 07

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

07:00
01/22/18
01/22
07:00
01/22/18
07:00
Recommendations
Apple analyst commentary  »

Wells Fargo maintains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

MB

Mindbody

$34.35

1.35 (4.09%)

06:59
01/22/18
01/22
06:59
01/22/18
06:59
Recommendations
Mindbody analyst commentary  »

Mindbody price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

06:58
01/22/18
01/22
06:58
01/22/18
06:58
Periodicals
Wal-Mart shops Brazil unit stake to Advent, other funds, Reuters reports »

Wal-Mart Stores is in…

WMT

Walmart

$104.59

0.29 (0.28%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 20

    Feb

HAL

Halliburton

$53.01

0.65 (1.24%)

06:54
01/22/18
01/22
06:54
01/22/18
06:54
Hot Stocks
Halliburton continues to experience delays in collecting payments in Venezuela »

Management said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

JNPR

Juniper

$27.85

0.19 (0.69%)

, AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

06:54
01/22/18
01/22
06:54
01/22/18
06:54
Upgrade
Juniper, Amazon.com rating change  »

Oppenheimer calls Amazon…

JNPR

Juniper

$27.85

0.19 (0.69%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 01

    Feb

  • 18

    Mar

HPQ

HP Inc.

$23.70

0.41 (1.76%)

06:54
01/22/18
01/22
06:54
01/22/18
06:54
Recommendations
HP Inc. analyst commentary  »

HP does not see sharp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

GEF

Greif

$60.82

1.13 (1.89%)

06:53
01/22/18
01/22
06:53
01/22/18
06:53
Conference/Events
Greif management to meet with Sidoti »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 29

    Mar

VR

Validus

$46.72

0.81 (1.76%)

, AIG

AIG

$61.55

0.02 (0.03%)

06:53
01/22/18
01/22
06:53
01/22/18
06:53
Hot Stocks
AIG to acquire Validus for $5.56B, or $68 per share, in cash »

American International…

VR

Validus

$46.72

0.81 (1.76%)

AIG

AIG

$61.55

0.02 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

  • 09

    Feb

  • 20

    Feb

  • 21

    Feb

HAL

Halliburton

$53.01

0.65 (1.24%)

06:52
01/22/18
01/22
06:52
01/22/18
06:52
Hot Stocks
Halliburton CEO: On path to to normalized margins in North America in 2018 »

"Outstanding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

VR

Validus

$46.72

0.81 (1.76%)

, AIG

AIG

$61.55

0.02 (0.03%)

06:52
01/22/18
01/22
06:52
01/22/18
06:52
Hot Stocks
Breaking Hot Stocks news story on Validus, AIG »

AIG to acquire Validus…

VR

Validus

$46.72

0.81 (1.76%)

AIG

AIG

$61.55

0.02 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

  • 09

    Feb

  • 20

    Feb

  • 21

    Feb

CELG

Celgene

$102.65

0.93 (0.91%)

, JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

06:51
01/22/18
01/22
06:51
01/22/18
06:51
Conference/Events
Celgene to host conference call »

Conference call to…

CELG

Celgene

$102.65

0.93 (0.91%)

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

HAL

Halliburton

$53.01

0.65 (1.24%)

06:50
01/22/18
01/22
06:50
01/22/18
06:50
Earnings
Halliburton reports Q4 adjusted cont ops EPS 53c, consensus 46c »

Reports Q4 revenue $5.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

BOH

Bank of Hawaii

$86.73

0.47 (0.54%)

06:49
01/22/18
01/22
06:49
01/22/18
06:49
Earnings
Bank of Hawaii reports Q4 EPS $1.01, consensus $1.07 »

Reports Q4 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

VR

Validus

$46.72

0.81 (1.76%)

06:49
01/22/18
01/22
06:49
01/22/18
06:49
Hot Stocks
Breaking Hot Stocks news story on Validus »

Validus trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

AIG

AIG

$61.55

0.02 (0.03%)

06:49
01/22/18
01/22
06:49
01/22/18
06:49
Hot Stocks
Breaking Hot Stocks news story on AIG »

AIG trading halted, news…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

  • 20

    Feb

  • 21

    Feb

CBU

Community Bank System

$55.39

0.84 (1.54%)

06:48
01/22/18
01/22
06:48
01/22/18
06:48
Hot Stocks
Community Bank System raises quarterly dividend to 34c from 32c per share »

During the fourth quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

BCS

Barclays

$11.14

0.07 (0.63%)

06:48
01/22/18
01/22
06:48
01/22/18
06:48
Periodicals
Tiger Global invests over $1B in Barclays, FT reports »

U.S. hedge fund Tiger…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBU

Community Bank System

$55.39

0.84 (1.54%)

06:47
01/22/18
01/22
06:47
01/22/18
06:47
Earnings
Community Bank System reports Q4 adjusted EPS 67c, consensus 71c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

HAWK

Blackhawk

$45.25

0.1 (0.22%)

06:47
01/22/18
01/22
06:47
01/22/18
06:47
Downgrade
Blackhawk rating change  »

Blackhawk downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.